Press releases
LATEST
2018
2017
2016
ARCHIVE
Jun 10, 2019
Sosei Heptares to receive new $3 million milestone payment from Pfizer, as it advances a second candidate from the GPCR collaboration for clinical development
May 24, 2019
Sosei Heptares notes that a valid Marketing Authorization Application for QVM149, a potential new inhaled combination therapy for asthma, has been filed with the European Medicines Agency
May 22, 2019
Sosei Heptares notes new positive Phase II data for QVM149, a potential novel inhaled combination for treating asthma, were presented at ATS 2019
May 14, 2019
Sosei Heptares reports progress with Pfizer as multi-target collaboration delivers first candidate for clinical advancement
May 14, 2019
Consolidated Financial Results for the First Quarter FY2019 (IFRS)
Apr 15, 2019
Sosei Heptares notes abstracts and posters reporting clinical and preclinical data from studies with immuno-oncology candidate AZD4635, presented by AstraZeneca at AACR 2019, are available
Apr 5, 2019
Securities Report for FY2018(Nine month period ended 31 December 2018)
Mar 28, 2019
Sosei Heptares commits to improve identified internal control weaknesses
Mar 27, 2019
Presentation for the 29th Ordinary General Meeting of Shareholders
Mar 27, 2019
29th Ordinary General Meeting of Shareholders Webcast
Mar 25, 2019
Sosei Heptares notes new clinical and preclinical data on next-generation immuno-oncology candidate AZD4635 will be presented at AACR 2019
Mar 22, 2019
Sosei Heptares announces that Ultibro® Breezhaler® and Seebri® Breezhaler® launched in China for the treatment of COPD
Mar 12, 2019
Sosei Heptares to introduce Restricted Share Units and Performance Share Units as new share-based incentive plans - Creating a globally consistent share-based incentive plan to encourage and reward corporate growth and better align with shareholders
Mar 5, 2019
Notice of the 29th Ordinary General Meeting of Shareholders
Mar 5, 2019
Information Disclosure on the Internet Regarding the Notice of the 29th Ordinary General Meeting of Shareholders
Mar 4, 2019
Sosei Heptares to Host Town Hall Meetings for Individual Shareholders in Nagoya and Osaka - Shinichi Tamura, Chairman and CEO, and Chris Cargill, CFO, to present
Mar 1, 2019
Notice regarding appointment of new External Director
Mar 1, 2019
Sosei Heptares announces minor correction to unaudited preliminary Consolidated Financial Results for FY2018 (IFRS)
Feb 20, 2019
Sosei Heptares starts new clinical development program - First subject dosed in Phase I study of HTL0030310, a selective SSTR5 (somatostatin 5) receptor agonist in development to treat endocrine disorders
Feb 12, 2019
Collaboration deal with Medicxi - Supplementary Material
Feb 12, 2019
Consolidated Financial Results for FY2018 (IFRS)
Feb 4, 2019
Collaboration deal with Medicxi Presentation
Feb 4, 2019
Sosei Heptares announces Medicxi to invest up to €40 million in new collaboration based on its orexin agonist program
Jan 31, 2019
Sosei Heptares to Launch ORAVI® Mucoadhesive Tablets 50mg for Oropharyngeal Candidiasis in Japan
Jan 8, 2019
37th Annual J.P. Morgan Healthcare Conference Presentation, January 7 2019
Jan 7, 2019
Sosei Heptares to receive US$15 million milestone payment from AstraZeneca with first partnered program moving towards Phase 2
Jan 1, 2019
New Year‘s message from CEO Shinichi Tamura
Dec 27, 2018
Sosei Heptares to present at 37th Annual J.P. Morgan Healthcare Conference in San Francisco
Dec 20, 2018
Sosei Heptares notes that MiNA Therapeutics has started enrolment of patients with advanced liver cancer in Phase 1b trial of MTL-CEBPA in combination with sorafenib
Dec 13, 2018
Sosei Heptares starts new clinical development program – First subject dosed in Phase I study of HTL0014242, a selective mGlu5 negative allosteric modulator in development to treat psychiatric and neurological disorders
Dec 12, 2018
Sosei Group Corporation announces changes in Executive Management team – Shinichi Tamura appointed as Chairman, President & Chief Executive Officer
Dec 3, 2018
Sosei Heptares – the world leader in GPCR drug design launches new name and corporate identity
Nov 8, 2018
FY2018 Q2 Results Conference Call Presentation Materials
Nov 8, 2018
Consolidated Financial Results for the Second Period FY2018 (IFRS)
Nov 7, 2018
Sosei enters collaboration to combine pioneering DNA technologies with StaR® technology to accelerate new drug discovery
Nov 1, 2018
Changes in Executive Management at Sosei
Oct 30, 2018
Sosei Completes Move to State-Of-The-Art R&D Facility
Oct 18, 2018
Sosei Decides not to Exercise its Option to Acquire Further Equity in MiNA (Holdings)
Sep 25, 2018
Sosei Announces Approval of ORAVI Mucoadhesive Tablets 50mg for Oropharyngeal Candidiasis in Japan
Sep 19, 2018
Sosei’s Strategic Minority Investment Company, MiNA Therapeutics, Announces Update From MTL-CEBPA Clinical Trial in Patients with Advanced Liver Cancer at International Liver Cancer Association Conference
Sep 18, 2018
Online Presentation - Update on development activities with HTL0018318
Sep 18, 2018
Sosei Provides Update on HTL0018318
Aug 30, 2018
Financial Data 2018
Aug 14, 2018
Securities Report for the First Quarter of 2018(Quarter ended 30 June 2018)
Aug 9, 2018
Consolidated Financial Results for the First Quarter FY2018 (IFRS)
Aug 6, 2018
Corporate Profile (Full Year FY2017) Now Available Online
Jun 22, 2018
Presentation for the 28th Ordinary General Meeting of Shareholders
Jun 22, 2018
28th Ordinary General Meeting of Shareholders Webcast
Jun 5, 2018
MiNA Therapeutics Presents Initial Results at ASCO from First-in-Human MTL-CEBPA Study in Advanced Liver Cancer Patients
Jun 4, 2018
Sosei Announces Appointment of Chris Cargill as Interim CFO
Jun 4, 2018
Notice of Withdrawal of New External Director Nomination
Jun 4, 2018
Notice of Changes in Executive Management at Sosei
May 25, 2018
Information Disclosure on the Internet Regarding the Notice of the 28th Ordinary General Meeting of Shareholders
May 25, 2018
Notice of the 28th Ordinary General Meeting of Shareholders
May 24, 2018
Sosei to Host Town Hall Meetings for Individual Shareholders in Nagoya and Osaka
May 24, 2018
Sosei collaboration with PeptiDream progressing well - Peptide antagonists with high affinity and selectivity against PAR2 target identified
May 22, 2018
Presentation Materials for the UBS Global Healthcare Conference
May 21, 2018
Sosei to Present at the UBS Global Healthcare Conference in New York
May 16, 2018
“Optimism for A2a” - Sosei’s AZD4635 covered in BioCentury
May 16, 2018
Notice of Partial Amendment to Articles of Incorporation
May 16, 2018
Notice of Change of Auditor
May 16, 2018
Sosei Group Corporation: Notice Regarding Appointment of New External Directors
May 11, 2018
Conference Call for FY2017 Full Year Results (Webcast)
May 10, 2018
FY2017 Full Year Results Conference Call Presentation Material
May 10, 2018
Notice of Stock Split and Partial Amendment to Articles of Incorporation
May 10, 2018
Notice of Changes in Accounting Period (End of Business Year)
May 10, 2018
Consolidated Financial Results for the FY2017 (IFRS)
Apr 25, 2018
Sosei Statement Regarding Vectura Group plc
Apr 18, 2018
Sosei confirms new data demonstrating AZD4635, a novel A2A receptor antagonist, induces anti-tumor immunity alone and in combination with anti-PD-L1 in preclinical models
Mar 19, 2018
2018 Investor Day WEBCAST, HTL0018318 for DLB in Japan by Dr Tim Tasker, CMO
Mar 19, 2018
2018 Investor Day WEBCAST, Pipeline Update by Dr Malcolm Weir, Chief R&D Office
Mar 19, 2018
2018 Investor Day WEBCAST Opening Remarks by Peter Bains, CEO
Mar 14, 2018
Sosei today hosted an Investor Day in Tokyo
Mar 14, 2018
2018 Investor Day Presentation, HTL0018318 for DLB in Japan, by Dr Tim Tasker, CMO
Mar 14, 2018
2018 Investor Day Presentation, Pipeline Update, by Dr Malcolm Weir, Chief R&D Officer
Mar 13, 2018
Sosei Regains Worldwide Rights from Teva to Develop and Commercialize Novel Small Molecule CGRP Antagonists for Migraine and Other Severe Headaches
Feb 22, 2018
Treatment with Ultibro® Breezhaler® improved cardiac function in COPD patients with lung hyperinflation
Feb 14, 2018
Sosei - Consolidated Financial Results for the Third Period FY2017 (IFRS)
Feb 8, 2018
Sosei provides an update on its immuno-oncology clinical program with AstraZeneca
Feb 2, 2018
Sosei Announces Restatements of Previously Issued Quarterly and Full Year Accounts
Feb 2, 2018
First Half FY2017 Corporate Update to Shareholders Now Available
Feb 2, 2018
Corporate Update Half Year Ended 30 Sep 2017
Jan 26, 2018
Sosei to Host Investor Day in Tokyo featuring 2017 Nobel Prize Winner Dr. Richard Henderson
Jan 19, 2018
Changes in Executive Management at Sosei
Jan 16, 2018
36th Annual J.P. Morgan Healthcare Conference
Jan 10, 2018
Sosei subsidiary, Heptares, enters drug R&D collaboration with Imperial College London focused on multiple GPCR disease target opportunities in the gastro-intestinal tract
Jan 8, 2018
Sosei to Present at 36th Annual J.P. Morgan Healthcare Conference in San Francisco
Jan 5, 2018
Conference Call for the 2nd Quarter of FY March 2018 (Webcast)
Jan 4, 2018
Heptares scientists solve structure of complement C5a receptor, an important drug target for inflammatory and neurodegenerative diseases, and cancer
Dec 22, 2017
Fixed terms to issue Stock Acquisition Rights
Nov 27, 2017
New data showed Ultibro® Breezhaler® significantly improved COPD patients’ lung function after direct switch from Seretide®
Nov 22, 2017
Sosei Announces Fixed Number of New Shares
Nov 22, 2017
Notice to issue Stock Acquisition Rights
Nov 20, 2017
Sosei Announces Determination of Issue Price
Nov 10, 2017
Sosei Announces Issuance of New Shares
Nov 9, 2017
H1 FY2017 Financial results and corporate update
Nov 9, 2017
Sosei to Advance Clinical Development in Japan of HTL0018318 in Patients with Dementia with Lewy Bodies (DLB)
Nov 9, 2017
Consolidated Financial Results for the 2nd Quarter FY2017 (IFRS)
Nov 8, 2017
Strategic Minority Investment Company MiNA Therapeutics enters into Collaboration and Licensing Agreement with Boehringer Ingelheim
Oct 20, 2017
Seebri™ Neohaler® (glycopyrrolate) Inhalation Powder is Now Available in the United States
Oct 5, 2017
Heptares Founder Richard Henderson Receives Nobel Prize in Chemistry 2017 for Pioneering Work in CRYO-EM for Visualising Biological Structures
Sep 19, 2017
Sosei announces key appointments of Head of Investor Relations and Corporate Communications and Group Financial Controller
Sep 1, 2017
First Subject Dosed in Phase1 Clinical Study of Novel Selective Muscarinic M4 Agonist in Development to Treat Major Symptoms of Alzheimer’s Disease
Sep 1, 2017
Heptares Enters a New Research and Drug Discovery Collaboration Under Its “ORBIT” Initiative With JUNTENDO Universit
Aug 10, 2017
Consolidated Financial Results for the First Quarter FY2017 (IFRS)
Aug 4, 2017
Notification of Change to Use of Funds
Aug 4, 2017
Notification of Disinvestment of Activus Pharma, a Sosei Subsidiary
Jul 13, 2017
Sosei Subsidiary Heptares Hosts Scientific Symposium in Celebration of 10-Year Anniversary
Jul 5, 2017
Presentation Material as of July 2017
Jul 5, 2017
Notice to Position and Policies Concerning the Reduction of the Minimum Investment Unit
Jun 30, 2017
27th Ordinary General Meeting of Shareholders Webcast
Jun 29, 2017
Sosei Subsidiary Heptares and PeptiDream Enter Strategic Collaboration to Discover, Develop & Commercialise Novel Therapeutics in Inflammatory Disease
Jun 28, 2017
Sosei Subsidiary Heptares Enters a New Research and Drug Discovery Collaboration under its “ORBIT” Initiative with New York University School of Medicine
Jun 20, 2017
Sosei Subsidiary Heptares Plans Relocation to Cambridge, UK
Jun 5, 2017
Notes to the Consolidated Financial Statements
Jun 1, 2017
Call for the 27th Ordinary General Meeting of Shareholders
May 31, 2017
Sosei Subsidiary Heptares Solves First Full-length Structure of GLP-1 Receptor Bound to Peptide Agonist
May 24, 2017
New analyses of FLAME study data reinforce the potential of Ultibro® Breezhaler® for COPD patients historically treated with steroids
May 22, 2017
Individual Investor Day 2017 Webcast
May 18, 2017
Sosei Subsidiary Heptares to Receive US$5 Million Milestone Payment from TEVA
May 18, 2017
Sosei Subsidiary Heptares’ Co-Founder and Chief Scientific Officer, Fiona MARSHALL, Receives 2017 John Daily Lecture Award in Recognition of Her Outstanding Contribution to GPCR Drug Discovery
May 16, 2017
Notice to issue Stock Acquisition Rights
May 16, 2017
Notice to issue Stock Acquisition Rights
May 12, 2017
FY2016 Results Conference Call, Presentation Material
May 12, 2017
Consolidated Financial Results for the FY2016 (IFRS)
May 12, 2017
Notice of the Difference from Financial Results Forecasts for the fiscal year ended March 31, 2017
May 3, 2017
Sosei Pays GBP 35 Million for an Equity Stake and Acquisition Option Agreement in MiNA Therapeutics
Apr 27, 2017
Sosei Subsidiary Heptares Collaboration with AstraZeneca Yields New Insights to Advance Drug Discovery in Pain, Cancer and Inflammation
Apr 5, 2017
Sosei subsidiary Heptares to Receive US$12 Million Milestone Payment from AstraZeneca
Apr 4, 2017
Availability of UTIBRON™ NEOHALER® (indacaterol/glycopyrrolate) Inhalation Powder in the United States
Mar 17, 2017
Sosei Announces its Intention to Remain Listed on the Mothers Market
Mar 13, 2017
Sosei subsidiary Heptares and Daiichi Sankyo to Discover and Develop Novel, Small-Molecules for the Treatment of Pain
Feb 28, 2017
Sosei announces submission of marketing authorization application of SO-1105 for oropharyngeal candidiasis
Feb 10, 2017
Notice Concerning Forecast Revision for the FY2016
Feb 10, 2017
Consolidated Financial Results for the 3rd Quarter FY2016 (IFRS)
Jan 31, 2017
Sosei Subsidiary Heptares Enters a New Drug R&D Collaboration under its “ORBIT” Initiative with the University of Cambridge
Jan 26, 2017
Achievement of sales milestone for COPD products
Jan 20, 2017
JITSUBO announced Execution of Joint Development and License Agreement
Jan 19, 2017
Sosei appoints Andrew Oakley as CFO
Dec 22, 2016
Out-licensing of COPD products in the US
Dec 9, 2016
Ultibro® Breezhaler® improved lung function and COPD symptoms after direct switch from previous treatment
Dec 8, 2016
Sosei subsidiary Heptares scientists solve structure of CCR9 Chemokine receptor offering unique opportunity to apply structure-based design across Chemokine receptor
Nov 30, 2016
Sosei subsidiaries Heptares to acquire G7 Therapeutics to extend leadership in GPCR-focused drug discovery and development
Nov 22, 2016
Major report recommends broad use of dual bronchodilators to treat COPD
Nov 15, 2016
Q2 FY2016 Results Conference Call, Presentation Material
Nov 14, 2016
Consolidated Financial Results for the 2nd Quarter FY2016 (IFRS)
Nov 11, 2016
Notification of Changes in Jitsubo, a Sosei Subsidiary, due to Capital Increase through Third-party Allocation of Shares.
Nov 10, 2016
Sosei subsidiaries Heptares and Jitsubo to develop novel GPCR-targeting peptide candidates for severe gastro-intestinal disorders
Oct 7, 2016
Sosei Subsidiary Heptares Therapeutics wins UK Best Established Biotech Company Award at OBN Annual Awards 2016
Sep 5, 2016
New findings confirm Ultibro® Breezhaler® is consistently more effective than Seretide® in reducing COPD flare-ups across different patient groups
Aug 29, 2016
Sosei announces completion of Japanese Phase III clinical study of SO-1105 for oropharyngeal candidiasis and achievement of principal endpoints
Aug 18, 2016
Sosei Subsidiary JITSUBO, Execution of Joint Development and Commercialization Agreement for Animal Ghrelin as a Veterinary Medicinal Product
Aug 10, 2016
Financial Data 2016
Aug 10, 2016
Consolidated Financial Results for the 1st Quarter FY2016 (IFRS)
Jul 6, 2016
Initiation of Phase 1 Clinical Study with Novel Immuno-Oncology Candidate Triggers USD10 Million Milestone Payment from AstraZeneca to Heptares
Jun 29, 2016
Sosei Subsidiary Heptares and leadXpro Enter Collaboration on Powerful New Approaches to GPCR Structure Determination for Drug Discovery
Jun 28, 2016
Presentation for the 26th Ordinary General Meeting of Shareholders
Jun 24, 2016
Sosei appoints Peter Bains as CEO
Jun 23, 2016
Sosei Subsidiary Sosei CVC launches RMF1
Jun 3, 2016
Notice of the 26th Ordinary General Meeting of Shareholders
May 26, 2016
Sosei Announces Hart-Scott-Rodino Clearance for Global Collaboration between its Subsidiary Heptares Therapeutics and Allergan
May 24, 2016
Individual Investor Day 2016, Presentation Material
May 16, 2016
Major study published in NEJM confirms Ultibro® Breezhaler® superiority over Seretide in preventing COPD exacerbations
May 16, 2016
FY2015 Results Conference Call, Presentation Material
May 13, 2016
Consolidated Financial Results FY2015
Apr 28, 2016
Sosei Subsidiary Heptares Chief Scientific Officer and Co-Founder Dr Fiona Marshall Elected As A Fellow of The Academy of Medical Sciences
Apr 25, 2016
Sosei Subsidiary Heptares Scientists Solve Structures of GLP-1 and Glucagon Receptors Enabling Structure-Based Design for Metabolic Disease
Apr 18, 2016
Sosei Subsidiary Heptares and Kymab enter strategic collaboration to discover, development and commercialise novel antibody therapeutics
Apr 7, 2016
Sosei Subsidiary Heptares and Allergan Announce Global R&D and Commercialization Partnership for Novel Treatments in Alzheimer’s and Other Neurological Disorders
Apr 7, 2016
Notice Concerning Forecast Revision
Apr 4, 2016
Sosei Subsidiary Heptares joins Pharma consortium applying state of the art Electron cryomicroscopy to advance structure cased drug discovery
Mar 22, 2016
Sosei appoints Peter Bains as COO and CEO-elect
Feb 10, 2016
Consolidated Financial Results for the Third Quarter FY2015 (IFRS)
Feb 10, 2016
Sosei subsidiary Heptares announces positive results from Phase 1b clinical trial with HTL9936, a first-in-class selective muscarinic M1 receptor agonist for improving cognition in dementia and schizophrenia
Dec 16, 2015
Sosei Announces Issuance of New Shares to Pfizer Seiyaku K.K. by way of Third Party Allotment
Dec 9, 2015
Commencement of First Phase III Trial of Inhaled Triple Therapy QVM149 for Asthma
Nov 30, 2015
Heptares Enters Strategic Drug Discovery Collaboration with Pfizer Inc. focused on GPCR Targets across Multiple Therapeutics Areas
Nov 25, 2015
Sosei Subsidiary Heptares and Teva Enter Agreement to Discover and Develop Novel Small Molecule CGRP Antagonists for Treatment of Migraine
Nov 17, 2015
FLAME Study Shows Superiority of Ultibro® Breezhaler® over Seretide in Reducing COPD Exacerbations
Nov 16, 2015
Q2 FY2015 Results Conference Call, Presentation Material
Nov 12, 2015
Consolidated Financial Results for the Second Quarter FY2015 (IFRS)
Oct 30, 2015
Sosei confirms FDA approvals of new dual combination bronchodilator Utibron Neohaler and monotherapy Seebri™ Neohaler® for patients with chronic obstructive pulmonary disease
Oct 21, 2015
”The story of how UK Biotech Heptares drives its clinical program after its acquisition by Sosei” - Pharma TV interviews Heptares CEO, Malcolm Weir
Oct 2, 2015
Heptares wins Best UK Biotech Dealmaker Award at OBN Annual Awards 2015
Sep 28, 2015
Sosei Subsidiary Heptares Awarded $5.5 Million Research & Development Grant from the US National Institute on Drug Abuse
Sep 28, 2015
Notice Concerning Signing of Syndicated Loan
Sep 18, 2015
Notice Concerning Determination of Number of New Shares to be Issued in respect of the Issuance of New Shares by way of Third-Party Allotment
Sep 14, 2015
Notice Concerning Determination of Number of New Shares to be Issued
Sep 9, 2015
Notice Concerning Determination of Issue Price and Selling Price
Sep 1, 2015
Notice Concerning Issuance of New Shares and Secondary Offering of Shares
Aug 17, 2015
Heptares’ Pipeline and Novel Approach to GPCR Structure-Guided Drug Discovery and Development Featured in BioCentury
Aug 12, 2015
Consolidated Financial Results for the First Quarter FY2015 (IFRS)
Aug 6, 2015
Sosei Subsidiary Heptares and AstraZeneca Enter Agreement to Develop Novel Immuno-Oncology Treatments for a Range of Cancers
Aug 4, 2015
MorphoSys and G7 Therapeutics Sign Alliance to Develop Innovative Antibody Therapeutics
Jul 30, 2015
Sosei subsidiary Heptares Initiates Proprietary Therapeutic Antibody Program against a GPCR Target
Jul 24, 2015
Sosei Announces Choice of Listing Markets
Jul 9, 2015
Financial Data 2015
Jun 25, 2015
The UK BioIndustry Association (BIA) published a new report, Celebrating UK bioscience: unravelling the stories behind UK bioscience success, in which it highlights the background to and the importance of the Heptares StaR® technology.
Jun 24, 2015
R&D Day, Presentation Material
Jun 23, 2015
Announcement of New Appointments
Jun 18, 2015
Planned development of inhaled triple therapy QVM149 for asthma
Jun 17, 2015
Sosei subsidiary Heptares announces positive outcome of Phase 1a study with first-ever selective muscarinic M1 receptor agonist for improving cognition in patients with Alzheimer’s disease
Jun 2, 2015
Call for the 25th Ordinary General Meeting of Shareholders
May 22, 2015
Heptares Scientist Wins Outstanding Young Chemist Award
May 21, 2015
Two positive US phase III programs in COPD for QVA149 and NVA237
May 14, 2015
Investor Day, Presentation Material
May 13, 2015
Consolidated Financial Results for FY2014 (IFRS)
May 13, 2015
FY2014 Results Conference Call, Presentation Material
Mar 6, 2015
U.S. FDA filing acceptance of NDAs for QVA149 and NVA237
Feb 23, 2015
Sosei Acquires Heptares Therapeutics for up to USD 400 million
Feb 12, 2015
Consolidated Financial Results for the Third Quarter FY2014 (financial year ending 31 March 2015) (IFRS)
Feb 2, 2015
Sosei Subsidiary Heptares launches ORBIT, a new collaborative R&D initiative designed to promote and broaden the application of its proprietary structure-based drug design expertise directed at G protein-coupled receptors (GPCRs)
Jan 8, 2015
Sosei confirms the submission of regulatory applications to US FDA and robust Phase III results for QVA149 and NVA237
Dec 11, 2014
Sosei acquires Jitsubo, a leading Japanese peptide technology company
Dec 3, 2014
Ultibro® Breezhaler® launched in the UK for the treatment of chronic obstructive pulmonary disease (COPD)
Nov 11, 2014
Consolidated Financial Results for the Second Quarter FY2014 (financial year ending 31 March 2015) (IFRS)
Sep 8, 2014
Positive results from three clinical trials presented at ERS 2014 further confirmed efficacy of Ultibro® Breezhaler® and Seebri® Breezhaler®, and promotion agreement with Pfizer in the UK
Aug 13, 2014
Sosei Announces Letter of Intent with Shin Nippon Biomedical Laboratories, and Project Finance
Aug 13, 2014
Consolidated Financial Results for the First Quarter FY2014 (financial year ending 31March 2015) (IFRS)
Jun 25, 2014
Consolidated Financial Results for FY2013 (IFRS)
May 28, 2014
Call for the 24th Ordinary General Meeting of Shareholders
May 21, 2014
Positive results at ATS for once-daily Ultibro® Breezhaler® versus combination therapy (tiotropium plus formoterol)
May 13, 2014
Financial Results (Kessan Tanshin) for FY2013 (fiscal year ended 31 March 2014) (Japanese GAAP) (Consolidated)
Apr 30, 2014
Once-daily Ultibro® Breezhaler® showed superior efficacy versus Seretide® for COPD patients in second head-to-head study, and the anticipated timing of China filing
Feb 17, 2014
Sosei announces initiation of development of two ophthalmic products
Feb 12, 2014
Consolidated Financial Report for the Third Quarter FY2013 (fiscal year ending 31 March 2014) (Japanese GAAP)
Feb 4, 2014
Sosei signs distribution agreement with FUJIFILM Pharma for commercialization of SO-1105
Jan 29, 2014
Update on Ultibro® Breezhaler® and Seebri® Breezhaler® for COPD
Jan 28, 2014
Sosei announces the transfer of Japan marketing authorization for NorLevo® TABLETS 0.75mg to ASKA Pharmaceuticals
Nov 20, 2013
Once-daily Ultibro® Inhalation Capsules (QVA149) for COPD launched in Japan
Nov 11, 2013
Consolidated Financial Report for the Second Quarter FY2013 (fiscal year ending 31 March 2014) (Japanese GAAP) (Consolidated)
Oct 15, 2013
Sosei receives 11th “Deloitte Technology Fast50 Japan” award
Sep 23, 2013
First in class once-daily dual bronchodilator Ultibro Breezhaler (QVA149) approved for the treatment of COPD in Europe
Sep 20, 2013
First in class once-daily dual bronchodilator Ultibro Inhalation Capsules (QVA149) approved for the treatment of COPD in Japan
Sep 9, 2013
Data at ERS further demonstrates efficacy of once-daily Ultibro® Breezhaler (QVA149) and Seebri® Breezhaler (glycopyrronium bromide)
Sep 4, 2013
QVA149 and glycopyrronium abstracts to be presented at ERS 2013
Aug 26, 2013
First in class once-daily dual bronchodilator QVA149 gains endorsement for approval from Drug Committee of MHLW (Ministry of Health, Labour and Welfare) for the treatment of COPD in Japan
Aug 9, 2013
Consolidated Financial Report for the First Quarter FY2013 (fiscal year ending 31 March 2014) (Japanese GAAP
Jul 27, 2013
First in class once-daily dual bronchodilator Ultibro® Breezhaler® (QVA149) gains positive CHMP opinion for the treatment of COPD
Jun 4, 2013
Sosei Announces Establishment of a Regenerative Medicine Fund
May 28, 2013
Announcement Concerning Partial Amendments To Articles Of Incorporation
May 22, 2013
New data reinforces strength of once-daily COPD portfolio in improving lung function, shortness of breath and reducing rate of exacerbations
May 14, 2013
Financial Results (Kessan Tanshin) for Financial Year Ended 31 March 2013 (Japanese GAAP) (Consolidated)
May 2, 2013
Sosei to Receive Grant from NEDO’s FY2012 Promotion Programme for Application of Innovative Technologies
Apr 24, 2013
Seebri Breezhaler GLOW 5 and GLOW 6 Phase III studies meet primary endpoint, and data from QVA149 SPARK Phase III study published in a medical journal
Mar 12, 2013
Sosei announces initiation of Phase III study for SO-1105 for the treatment of oropharyngeal candidiasis
Mar 1, 2013
Announcement Concerning Share Split, Adoption of Share-Trading-Unit System, and Partial Changes to Articles of Incorporation
Feb 13, 2013
Summary of Consolidated Financial Results for the Q3 ended 31 December 2012 (abridged English version)
Nov 22, 2012
Seebri® Inhalation Capsules 50 mcg, a new once-daily treatment for the symptoms of COPD, launched in Japan by licensing partner
Nov 9, 2012
Summary of Consolidated Financial Results for the Q2 ended 30 September 2012 (abridged English version)
Nov 7, 2012
QVA149 filed by licensing partner as a once-daily maintenance treatment for COPD in Japan
Oct 25, 2012
QVA149 filed as a once-daily maintenance treatment for COPD in Europe
Oct 1, 2012
Seebri Breezhaler receives European Commission approval as once-daily maintenance treatment for COPD in the EU
Sep 28, 2012
Seebri Inhalation Capsules receive MHLW approval as once-daily maintenance treatment for COPD in Japan
Sep 6, 2012
The Pharmaceutical Affairs and Food Sanitation Council of MHLW recommended approval for NVA237 (glycopyrronium bromide) licensed to Novartis by Sosei
Sep 3, 2012
Data at ERS shows efficacy of once-daily COPD portfolio versus comparators, further establishes dual-bronchodilator QVA149
Aug 28, 2012
QVA149 Phase III study meets primary endpoint in reducing exacerbations in COPD patients and filings in EU and Japan by end of year
Aug 13, 2012
Sosei assigns SD118 assets to Beijing Tide Pharmaceutical
Aug 8, 2012
Summary of Consolidated Financial Results for the Q1 ended 30 June 2012 (abridged English version)
Jul 2, 2012
Sosei announces successful completion of Phase I study for SO-1105 for the treatment of oropharyngeal candidiasis
Jun 23, 2012
Once-daily Seebri Breezhaler receives positive CHMP opinion to treat COPD patients in the EU
May 17, 2012
NVA237 Phase III GLOW2 data at American Thoracic Society (ATS) International Conference and Phase II clinical trial update
May 15, 2012
Summary of Consolidated Financial Results for the Financial Year ended 31 March 2012 (abridged English version)
Apr 24, 2012
QVA149 ILLUMINATE Phase III COPD study meets primary endpoint and clarification of anticipated timing of US filings for NVA237 and QVA149
Apr 2, 2012
QVA149 phase III COPD studies met primary endpoints
Mar 8, 2012
Sosei Announces Initiation of Phase I study for SO-1105
Mar 8, 2012
Sosei Announces Private Placement of New Shares by its Subsidiary (abridged English translation)
Feb 10, 2012
Summary of Consolidated Financial Results for 3Q ended 31 December 2011 (abridged English version)
Jan 23, 2012
Sosei Announces Collaboration with CEOLIA Pharma
Nov 25, 2011
Novartis files NDA for NVA237 as a treatment for chronic obstructive pulmonary disease (COPD) in Japan
Nov 14, 2011
Summary of Consolidated Financial Results for the First Half Year ended 30 September 2011 (abridged English version)
Oct 25, 2011
Update on US NDA timelines for NVA237 and QVA149
Sep 27, 2011
NVA237 filed in Europe and positive Phase III data at European Respiratory Society Congress
Aug 22, 2011
Sosei to Receive Grant from NEDO’s FY2011 Innovation Promotion Programme for Development of Innovative Ophthalmic Solutions
Aug 12, 2011
Summary of Consolidated Financial Results for the Q1 ended 30 June 2011 (abridged English version)
Jun 30, 2011
Phase III study shows once-daily NVA237 is superior to placebo and similar to tiotropium in improving lung function in COPD
Jun 20, 2011
Sosei Announces Collaboration with Gifu Pharmaceutical University
May 23, 2011
Sosei to Launch NorLevo® TABLETS 0.75mg (Emergency Contraceptive Pill) in Japan
May 12, 2011
Sosei Announces Collaboration with Toa Pharmaceuticals and Nitto Medic
May 12, 2011
Summary of Consolidated Financial Results for the Financial Year ended 31st March 2011 (abridged English version )
May 11, 2011
Sosei Acquires Development and Commercialization Rights to Loramyc from BioAlliance Pharma
Apr 19, 2011
Phase III data show NVA237 significantly improves lung function with good safety profile in COPD patients
Feb 23, 2011
Sosei Receives Approval from Japan MHLW for NorLevo TABLETS 0.75mg Emergency Contraceptive Pill
Feb 14, 2011
Summary of Consolidated Financial Results for the 3Q ended 31 December 2010
Dec 24, 2010
Department on Drugs of the Japanese Ministry of Health, Labour and Welfare (MHLW) recommends the approval of emergency contraceptive NorLevo (SOH-075)
Nov 11, 2010
Summary of Consolidated Financial Results for the First Half Year ended 30 September 2010
Oct 21, 2010
Update on NVA237 and QVA149 for COPD
Sep 6, 2010
Sosei Announces Issuance of Stock Options (Stock Acquisition Rights)
Aug 17, 2010
Sosei Acquires Activus Pharma
Aug 12, 2010
Summary of Consolidated Financial Results for the 1Q ended 30 June 2010
Jun 21, 2010
Sosei to Acquire Activus Pharma
May 31, 2010
Sosei Announces a New Appointment to its Board of Directors
May 31, 2010
Sosei Announces Stock Option (Stock Acquisition Rights) Allotment
May 13, 2010
Summary of Consolidated Financial Results for the Financial Year ended 31 March 2010 (abridged English version )
May 10, 2010
Sosei Announce Start of Phase III Clinical Study with QVA149
Feb 12, 2010
Summary of Consolidated Financial Results for the 3Q ended 31 December 2009
Jan 6, 2010
Update on Phase I Clinical Study of RS(+) Mefloquine for Malaria
Nov 12, 2009
Summary of Consolidated Financial Results for the First Half Year ended 30th September 2009
Nov 2, 2009
Sosei Signs Definitive Distribution Agreement with ASKA for Commercialisation of SOH-075 (NorLevo®)
Oct 22, 2009
Update on NVA237 and QVA149 for Chronic Obstructive Pulmonary Disease
Oct 14, 2009
Sosei Announces Deal with UK Biotech Company
Oct 6, 2009
Sosei Assigns AD 923 Assets to Pharmasol
Sep 30, 2009
Sosei Announces Filing of NDA for SOH-075 (NorLevo) in Japan
Sep 16, 2009
QVA149 Phase II Data Presented at the European Respiratory Society Annual Meeting
Aug 12, 2009
Summary of Consolidated Financial Results for the 1Q ended 30th June 2009 (abridged English version)
Jul 3, 2009
Sosei Announces Enrolment of First Patient in Phase III Clinical Study with NVA237
Jun 29, 2009
Sosei and Vectura Announce Start of Phase III Clinical Study with NVA237
May 20, 2009
NVA237 Manufacturing Process Related Patent Granted in Europe (Summary of Japanese PR)
May 14, 2009
Summary of Consolidated Financial Results for the Financial Year ended 31st March 2009 (abridged English version )
Mar 16, 2009
SD118 Patent Granted in Europe (Summary of Japanese PR)
Mar 5, 2009
Sosei sells chronotherapeutics patents (summary of Japanese PR)
Feb 27, 2009
Announcement of New Appointments
Feb 10, 2009
Summary of Consolidated Financial Results for the 3Q ended 31st December 2008
Dec 26, 2008
Sosei Announces Buyback of the Commercialization Rights to AD 923 from Mundipharma
Dec 26, 2008
Revision Announcement of Financial Forecasts for FY2008
Dec 8, 2008
Sosei Confirms the Safety of SD118 in Two Phase I Trials
Nov 26, 2008
Sosei Announces the Out-licensing of RS(+) Mefloquine to Treague Ltd for theTreatment and Prophylaxis of Malaria
Nov 19, 2008
Neurosolutions and Sosei Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting
Nov 6, 2008
Summary of Consolidated Financial Results for the First Half Year ended 30th September 2008 (abridged English version )
Oct 22, 2008
Sosei Agrees Terms with ASKA for Commercialisation of SOH-075 (NorLevo®).
Oct 7, 2008
NVA237 Phase II results presented at the European Respiratory Society Annual Meeting show promising efficacy and tolerability with potentially faster onset than tiotropium.
Aug 12, 2008
Summary of Consolidated Financial Results for the 1Q ended 30th June 2008
Jul 10, 2008
Sosei Announces Completion of Phase III Trial for NorLevo
May 14, 2008
Sosei Announces Outcome of Strategy Review
May 14, 2008
Summary of Consolidated Financial Results for the Fiscal Year Ended March 31, 2008 (abridged English version)
Mar 26, 2008
Sosei Announces Temporary Halt to AD 923 CBP Phase III Studies in Europe
Feb 20, 2008
Sosei Announces Initiation of Phase III Trial for NorLevo
Feb 12, 2008
Sosei Announces Start of AD 923 Phase III Studies in Europe
Feb 12, 2008
Summary of Consolidated Financial Results for the 3Q ended 31st December 2007
Jan 18, 2008
Update of NVA237 and QVA149 Development Programme
Dec 13, 2007
Sosei and Vectura Announce Start of Phase II Efficacy Study of QVA149
Dec 7, 2007
Sosei Announces New Fundraising
Nov 28, 2007
Sosei Announces Approval to Start AD 923 Phase III Studies in Europe
Nov 27, 2007
Sosei Announces Update on Phase I Trials for SD118
Nov 15, 2007
Sosei and Vectura Announce Start of Phase II Studies of QVA149 for the Treatment of COPD
Nov 14, 2007
Summary of Consolidated Financial Results for the First Half Year ended 30th September 2007
Sep 18, 2007
Sosei Announces Completion of Phase II Trial of AD 337 in Fibromyalgia Syndrome
Aug 13, 2007
Sosei Announces Completion of Phase I Trial for NorLevo
Aug 10, 2007
Summary of Consolidated Financial Results for the First Quarter ended 30th June 2007
Aug 6, 2007
Sosei and Vectura Announce Start of Phase II Clinical Study with NVA237 in the USA
Jul 18, 2007
Vectura and Sosei Announce NVA237 Dose Ranging Study in New Device
May 29, 2007
Sosei Announces Start of SD118 Phase I Studies
May 25, 2007
Sosei Announces New Appointments to its Board of Directors
May 22, 2007
Sosei Announces Successful Completion of AD 923 Pharmacokinetic Study in the USA
May 14, 2007
Summary of Consolidated Financial Results for the Fiscal Year Ended March 31, 2007
Mar 12, 2007
Sosei Announces Completion of Exercise of Stock Acquisition Rights
Mar 8, 2007
Sosei Announces Significant Exercise of Stock Acquisition Rights
Mar 7, 2007
Sosei Announces Significant Exercise of Stock Acquisition Rights
Mar 5, 2007
AD 923 Commences Phase I Clinical Development in the USA
Mar 1, 2007
Sosei Announces Significant Exercise of Stock Acquisition Rights
Feb 21, 2007
Sosei Announces Progression of SD118 Towards Phase 1 Studies
Feb 8, 2007
Summary of Consolidated Financial Results for the 3Q Ended 31st December 2006 (Abridged English version)
Jan 30, 2007
Sosei Announces Significant Exercise of Stock Acquisition Rights
Jan 5, 2007
Sosei Announces New Fundraising
Nov 29, 2006
Sosei Announces that QVA149 Clinical Development starts in 2007 and Updates the Status of NVA237
Nov 21, 2006
Sosei Announces Results of AD 452 Phase IIb Clinical Trial
Nov 17, 2006
Sosei Announces Initiation of Phase I Trial for NorLevo
Nov 9, 2006
Announcement of New Appointments
Nov 9, 2006
Summary of Consolidated Financial Results for the First Half ended 30th September 2006
Nov 2, 2006
Revision Announcement of Financial Forecasts for FY2006
Oct 17, 2006
Sosei Announces Start of Phase II Trial of AD 337 in Fibromyalgia Syndrome
Aug 11, 2006
Summary of Consolidated Financial Results for the First Quarter ended 30th June 2006 (abridged English version)
Jun 28, 2006
Sosei and Vectura Announce Successful Completion of Phase IIb Trial of NVA237 for COPD
Jun 27, 2006
Sosei Announces Agreement with Mundipharma for AD 923
Jun 27, 2006
Revision Announcement of Financial Forecast for FY2006
Jun 22, 2006
Sosei Business Strategy Update and Portfolio Review
May 15, 2006
Consolidated Financial Results for the Fiscal Year Ended March 31, 2006
May 15, 2006
Sosei Announces Reorganisation of its Corporate Structure Under Holding Company
May 15, 2006
Sosei Discontinues Development of SOU-001
May 15, 2006
Sosei Announces Company Name Change of two Affiliates
May 11, 2006
Revision Announcement of Financial Forecasts for FY2005
Mar 31, 2006
Sosei sells off its subsidiary, SC Consulting
Mar 31, 2006
Announcement of New Appointments
Feb 2, 2006
Amendment of Consolidated Financial Results for 9 Months Ended 31 Dec. 2005
Jan 20, 2006
Sosei updates the status of Eligard
Dec 19, 2005
Sosei Sub-licenses NorLevo to Hexal for Australia
Dec 16, 2005
Sosei Business Update and Revised Financial Forecast Following Acquisition of Arakis
Nov 14, 2005
Revision Announcement of Financial Forecast for FY2005
Nov 1, 2005
Arakis Completes Phase I Trials of AD 337 in Fibromyalgia Syndrome
Oct 17, 2005
Arakis and Vectura Announce Start of Phase IIb Trial of NVA237 for COPD
Oct 5, 2005
H.G.F. License Contract
Sep 5, 2005
Arakis Commences Phase IIB Trial for Rheumatoid Arthritis Drug
Jul 19, 2005
Sosei to Acquire Arakis for £106.5 million
Jun 28, 2005
NeuroSolutions’ Collaboration with Sosei’s Drug Reprofiling Platform Yields Possible New Treatment for Neuropathic Pain
Jun 20, 2005
Sosei’s SOU-001 Project Moves to Phase II Clinical Study
May 24, 2005
Sosei Adopts ”Company with Committees” System
Mar 16, 2005
Sosei Appoints David Chiswell as Non-Executive Chairman
Mar 4, 2005
Itochu and Sosei Agree on Capital and Business Alliances
Feb 28, 2005
Sosei Files Marketing Authorisation Application for SOT-375
Feb 23, 2005
Sosei In-License Urology Drug From Otsuka
Feb 14, 2005
SOT-107 Granted Orphan Designation in Japan
Feb 10, 2005
EPS and SOSEI Establish a Biopharmaceutical JV in China
Jan 24, 2005
Lead antibodies identified under SOA-002 project collaboration
Nov 1, 2004
Sosei announces the launch of its US company targeting the development of CNS compounds. Deal with Mitsubishi Pharma Corporation provides the platform.
Oct 22, 2004
Announcement on Revision of Financial Forecast for FY2004
Sep 16, 2004
Announcement of New Appointments
Jul 29, 2004
Announcement of Movement in Major Shareholders
Jun 25, 2004
Announcement of Earnings Forecast For FY2004
Jun 15, 2004
Sosei Initiates Phase I Clinical Trial of Oral SOU-001
LATEST
2018
2017
2016
ARCHIVE